The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking

RDF 

 
Το τεκμήριο παρέχεται από τον φορέα :
Ελληνική Γαστροεντερολογική Εταιρία
Αποθετήριο :
Annals of Gastroenterology
δείτε την καρτέλα τεκμηρίου
μέσα από τον ιστότοπο του αποθετηρίου του φορέα *
κοινοποιήστε το τεκμήριο



Σημασιολογικός εμπλουτισμός/ομογενοποίηση από το EKT

2016 (EL)
The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking (EN)

Konstantinides, Polidoros; General Hospital of Athens "Hippokratio"
Kontopidou, Flora N.; General Hospital of Athens "Hippokratio"
Kanellopoulou, Theoni; General Hospital of Athens "Hippokratio"
Papatheodoridis, George V.; General Hospital of Athens "Laiko"
Alexopoulou, Alexandra; General Hospital of Athens "Hippokratio"

None (EN)

Background Platelet microparticles (PMPs) are platelet-derived membrane vesicles involved in cardiovascular diseases and atherosclerosis. Chronic hepatitis C (CHC) is associated with increased atherosclerosis, but the effect of therapy on its atherogenic potential has not been adequately studied.Methods We evaluated PMP levels before and after treatment with pegylated-interferon-alfa and ribavirin in 28 CHC patients compared with 20 non-alcoholic fatty liver disease (NAFLD) patients and 20 healthy volunteers (HV).Results Twenty-four (86%) CHC patients achieved sustained virological response (SVR). PMP levels were determined at baseline in CHC, NAFLD patients, and HV, and at end-of-treatment (EOT) and 24 weeks post-treatment (SVR24) in CHC patients. PMP levels at baseline were higher in CHC than NAFLD patients (P<0.001) and HV (P=0.007). Higher PMPs at baseline were observed in smokers than non-smokers with CHC (P=0.006). Among smokers from all groups, PMPs at baseline were higher in CHC than NAFLD patients (P=0.001) and HV (P=0.024). In CHC patients, PMPs declined from baseline to both EOT (P=0.035) and SVR24 (P=0.006). Only CHC patients with SVR had a significant decline in PMPs from baseline to SVR24 (P=0.018). PMPs at ΕΟΤ and SVR24 in all CHC patients were similar to PMPs in NAFLD patients and HV.Conclusions PMP levels are increased in CHC patients, particularly smokers, which further supports the atherosclerotic potential of CHC and suggests a potentially synergistic effect of smoking and CHC on the atherosclerotic process. Since PMP levels in CHC patients with SVR were similar to NAFLD patients and HV, the atherosclerotic potential of CHC seems to be abolished by effective antiviral treatment.Keywords Atherosclerosis, hepatitis C, interferon, platelet microparticles, smokingAnn Gastroenterol 2016; 29 (2): 201-207DOI: http://dx.doi.org/10.20524/aog.2016.0013 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2016-04-01


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 29, No 2 (2016); 201 (EN)



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.